Biomarin Pharmaceutical (BMRN) Change in Acquisitions & Divestments (2009 - 2026)

Biomarin Pharmaceutical has disclosed Change in Acquisitions & Divestments across 18 years of filings, most recently posting $767.3 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 886.17% year-over-year to $767.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 77.33% YoY) and the FY2025 annual result came in at $337.8 million, down 46.64% from the prior year.
• Change in Acquisitions & Divestments advanced to $767.3 million in Q1 2026, from $43.3 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $767.3 million in Q1 2026 and troughed at $43.3 million in Q4 2025.
• A 5-year average of $189.6 million and a median of $155.8 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2025 — Change in Acquisitions & Divestments plunged 72.02% — and 2026, when it jumped 886.17%.
• Tracing BMRN's Change in Acquisitions & Divestments over 5 years: stood at $142.8 million in 2022, then retreated by 20.71% to $113.2 million in 2023, then jumped by 36.57% to $154.6 million in 2024, then tumbled by 72.02% to $43.3 million in 2025, then jumped by 1673.89% to $767.3 million in 2026.
• Business Quant data shows BMRN's Change in Acquisitions & Divestments at $767.3 million in Q1 2026, $43.3 million in Q4 2025, and $98.8 million in Q3 2025.